A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study To Evaluate The Efficacy And Safety Of PF-04236921 In Subjects With Systemic Lupus Erythematosus (SLE).

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study To Evaluate The Efficacy And Safety Of PF-04236921 In Subjects With Systemic Lupus Erythematosus (SLE).

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs PF 4236921 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms BUTTERFLY
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Sep 2016 Primary endpoint (Systemic Lupus Erythematosus Responder Index at 24 weeks) has not been met, according to results published in the Annals of the Rheumatic Diseases.
    • 26 Sep 2016 Results assessing safety and efficacy published in the Annals of the Rheumatic Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top